Under the US Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? In a podcast episode of Our Curious Amalgam, titled “Biologically similar but competitively not so? Economic considerations of IP litigation settlements involving biosimilars” Sean Sheridan and Archan Ruparel speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more.
CRA promotes 11 to vice president, strengthening expertise across the firm
“The achievements of our newly promoted Vice Presidents reflect the great year that CRA had in 2025 and reinforce my optimism in our future,” said CRA...